New Insights into the Epigenetics of Hepatocellular Carcinoma

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2017 Apr 13

PMID 28401148

Citations 45

Authors

Braira Wahid

Amjad Ali

Shazia Rafique

Muhammad Idrees

Affiliations

Soon will be listed here.

Abstract

Hepatocellular Carcinoma (HCC) is one of the most predominant malignancies with high fatality rate. This deadly cancer is rising at an alarming rate because it is quite resistant to radio- and chemotherapy. Different epigenetic mechanisms such as histone modifications, DNA methylation, chromatin remodeling, and expression of noncoding RNAs drive the cell proliferation, invasion, metastasis, initiation, progression, and development of HCC. These epigenetic alterations because of potential reversibility open way towards the development of biomarkers and therapeutics. The contribution of these epigenetic changes to HCC development has not been thoroughly explored yet. Further research on HCC epigenetics is necessary to better understand novel molecular-targeted HCC treatment and prevention. This review highlights latest research progress and current updates regarding epigenetics of HCC, biomarker discovery, and future preventive and therapeutic strategies to combat the increasing risk of HCC.

Citing Articles

The epigenetic basis of hepatocellular carcinoma - mechanisms and potential directions for biomarkers and therapeutics.

Lin H, Jeon A, Chen K, Lee C, Wu L, Chong S Br J Cancer. 2025; .

PMID: 40057667 DOI: 10.1038/s41416-025-02969-8.

Novel histone modifications and liver cancer: emerging frontiers in epigenetic regulation.

Wang Z, Liu Z, Lv M, Luan Z, Li T, Hu J Clin Epigenetics. 2025; 17(1):30.

PMID: 39980025 PMC: 11841274. DOI: 10.1186/s13148-025-01838-8.

Current status and new directions for hepatocellular carcinoma diagnosis.

Tu J, Wang B, Wang X, Huo K, Hu W, Zhang R Liver Res. 2025; 8(4):218-236.

PMID: 39958920 PMC: 11771281. DOI: 10.1016/j.livres.2024.12.001.

Targeting microRNA methylation: Innovative approaches to diagnosing and treating hepatocellular carcinoma.

Sufianov A, Agaverdiev M, Mashkin A, Ilyasova T Noncoding RNA Res. 2025; 11():150-157.

PMID: 39829957 PMC: 11742574. DOI: 10.1016/j.ncrna.2024.12.002.

Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application.

Su L, Bu J, Yu J, Jin M, Meng G, Zhu X Clin Transl Med. 2024; 14(11):e70066.

PMID: 39462685 PMC: 11513202. DOI: 10.1002/ctm2.70066.

References

Esteller M, Corn P, Baylin S, Herman J . A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61(8):3225-9. View

Herceg Z . Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis. 2007; 22(2):91-103. DOI: 10.1093/mutage/gel068. View

Bishayee A, Waghray A, Barnes K, Mbimba T, Bhatia D, Chatterjee M . Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm Res. 2010; 27(6):1080-91. DOI: 10.1007/s11095-010-0144-4. View

Falkenberg K, Johnstone R . Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014; 13(9):673-91. DOI: 10.1038/nrd4360. View

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

Tomasi M, Li T, Li M, Mato J, Lu S . Inhibition of human methionine adenosyltransferase 1A transcription by coding region methylation. J Cell Physiol. 2011; 227(4):1583-91. PMC: 3183271. DOI: 10.1002/jcp.22875. View

Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M . Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology. 2007; 72(1-2):69-74. DOI: 10.1159/000111106. View

Magerl C, Ellinger J, Braunschweig T, Kremmer E, Koch L, Holler T . H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. Hum Pathol. 2009; 41(2):181-9. DOI: 10.1016/j.humpath.2009.08.007. View

Zhang Y . Detection of epigenetic aberrations in the development of hepatocellular carcinoma. Methods Mol Biol. 2014; 1238:709-31. DOI: 10.1007/978-1-4939-1804-1_37. View

10.

Song M, Tiirikainen M, Kwee S, Okimoto G, Yu H, Wong L . Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma. PLoS One. 2013; 8(2):e55761. PMC: 3577824. DOI: 10.1371/journal.pone.0055761. View

11.

Hernando-Herraez I, Garcia-Perez R, Sharp A, Marques-Bonet T . DNA Methylation: Insights into Human Evolution. PLoS Genet. 2015; 11(12):e1005661. PMC: 4684328. DOI: 10.1371/journal.pgen.1005661. View

12.

Chen C, Tseng Y, Wu J, Chen G, Lin K, Hwang S . Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and MicroRNA regulation. Biomaterials. 2015; 44:71-81. DOI: 10.1016/j.biomaterials.2014.12.023. View

13.

Zhu J . DNA methylation and hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2006; 13(4):265-73. DOI: 10.1007/s00534-005-1054-4. View

14.

Lin C, Gong H, Tseng H, Wang W, Wu J . miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2008; 375(3):315-20. DOI: 10.1016/j.bbrc.2008.07.154. View

15.

Ye C, Tao R, Cao Q, Zhu D, Wang Y, Wang J . Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma. Int J Oncol. 2016; 49(2):589-602. DOI: 10.3892/ijo.2016.3535. View

16.

Zhang D, Cao C, Liu L, Wu D . Up-regulation of LncRNA SNHG20 Predicts Poor Prognosis in Hepatocellular Carcinoma. J Cancer. 2016; 7(5):608-17. PMC: 4820738. DOI: 10.7150/jca.13822. View

17.

Zhao L, Wang W . miR-125b suppresses the proliferation of hepatocellular carcinoma cells by targeting Sirtuin7. Int J Clin Exp Med. 2016; 8(10):18469-75. PMC: 4694354. View

18.

Zhang L, Guo Y, Zhao C, Gao J . Effects and mechanism of miR-214 on hepatocellular carcinoma. Asian Pac J Trop Med. 2015; 8(5):392-8. DOI: 10.1016/S1995-7645(14)60350-3. View

19.

Tang X, Ge L, Chen Z, Kong S, Liu W, Xu Y . Methylation of the Constitutive Androstane Receptor Is Involved in the Suppression of CYP2C19 in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Drug Metab Dispos. 2016; 44(10):1643-52. DOI: 10.1124/dmd.116.070243. View

20.

Quagliata L, Matter M, Piscuoglio S, Arabi L, Ruiz C, Procino A . Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology. 2013; 59(3):911-23. PMC: 3943759. DOI: 10.1002/hep.26740. View